Spoken Alpha
Immuneering Corp
Immuneering Corp develops Deep Cyclic Inhibitors, a novel class of oral cancer drugs designed to cyclically disrupt tumor cell signaling pathways while sparing healthy cells. The company's lead candidate, atebimetinib, targets the MAPK pathway in solid tumors including pancreatic and lung cancers, and is in late-stage clinical trials.
Immuneering Corp is a Healthcare company operating in Biotechnology with a $276.3M market cap.
IMRX missed consensus EPS by 0.0% in Q2 FY2026, reported Aug 4, 2026.
2 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for IMRX.
$ curl https://api.spokenalpha.com/v1/companies/IMRXFAQ
Spoken Alpha indexes IMRX's earnings call transcripts at https://spokenalpha.com/companies/IMRX. Each call links to attributed speakers and parsed analyst Q&A. Immuneering Corp's own investor relations page is at https://ir.immuneering.com/investor-relations.
Immuneering Corp (IMRX) held its most recent earnings call on 2025-11-12, covering fiscal Q3 2025.
Immuneering Corp (IMRX) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-04 | $-0.27 | $-0.26 | -3.9% | $361.0K | — | — | EODHD |
| Q1 FY2026 | 2026-05-11 | $-0.21 | $-0.35 | +40.0% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-05 | $-0.18 | $-0.31 | +41.9% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-0.38 | $-0.39 | +2.6% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-12 | $-0.40 | $-0.40 | 0.0% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-04 | $-0.42 | $-0.58 | +27.6% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-19 | $-1.07 | $-0.45 | -100.0% | $726.3K | — | — | EODHD |
| Q3 FY2024 | 2024-11-12 | $-0.49 | $-0.55 | +10.9% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-05 | $-0.47 | $-0.53 | +11.3% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-06 | $-0.49 | $-0.50 | +2.0% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-02-29 | $-0.52 | $-0.47 | -10.6% | $-94.4M | — | — | EODHD |
| Q3 FY2023 | 2023-11-08 | $-0.43 | $-0.49 | +12.2% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-02 | $-0.43 | $-0.53 | +18.9% | $94.4M | — | — | EODHD |
| Q1 FY2023 | 2023-05-03 | $-0.51 | $-0.56 | +8.9% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-05 | $-0.50 | $-0.58 | +13.8% | $455 | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $-0.49 | $-0.48 | -2.1% | $38.4K | — | — | EODHD |
| Q2 FY2022 | 2022-08-09 | $-0.44 | $-0.52 | +15.4% | $94.4K | — | — | EODHD |
| Q1 FY2022 | 2022-05-09 | $-0.49 | $-0.44 | -11.4% | $183.7K | — | — | EODHD |
| Q4 FY2021 | 2022-03-09 | $-0.42 | $-0.39 | -7.7% | $189.6K | — | — | EODHD |
| Q3 FY2021 | 2021-11-08 | $-0.47 | $-0.62 | +24.2% | $482.1K | — | — | EODHD |
Source: EODHD. IMRX reported actuals as published; sparse fields render as —.